marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q3
added 11-04-2024
Editas Medicine Balance Sheet 2011-2024 | EDIT
Annual Balance Sheet Editas Medicine
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-87.1 M | -97.6 M | -181 M | - | -209 M | -102 M | -106 M | -140 M | 56.7 M | -10.2 M | 99 K | - | - |
Long Term Debt |
24.4 M | 32.9 M | 16.1 M | - | - | - | - | - | 200 M | 344 K | 2.11 M | - | - |
Long Term Debt Current |
12.2 M | 11.1 M | 10.3 M | 6.81 M | 5.8 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 186 M | 148 M | 128 M | 61.5 M | 226 M | 21.3 M | 2.12 M | - | - |
Total Current Liabilities |
63.2 M | 60.1 M | 46.9 M | 58.2 M | 60 M | 35.9 M | 36.7 M | 33.1 M | - | - | - | - | - |
Total Liabilities |
150 M | 154 M | 124 M | 179 M | 246 M | 184 M | 165 M | 94.6 M | 232 M | 27.5 M | 4.24 M | - | - |
Deferred Revenue |
8.22 M | 8.22 M | 11.3 M | 20.9 M | 23.5 M | 15.7 M | 13.2 M | - | 88 K | - | - | - | - |
Retained Earnings |
-1.23 B | -1.08 B | -858 M | -665 M | -549 M | -416 M | -306 M | -186 M | -88.3 M | -15.4 M | -1.76 M | - | - |
Total Assets |
499 M | 514 M | 677 M | 573 M | 509 M | 420 M | 373 M | 229 M | 149 M | 12.2 M | 2.48 M | - | - |
Cash and Cash Equivalents |
124 M | 142 M | 207 M | 144 M | 238 M | 135 M | 147 M | 185 M | 143 M | - | - | - | - |
Book Value |
349 M | 361 M | 554 M | 394 M | 262 M | 236 M | 208 M | 135 M | -83.1 M | -15.3 M | -1.76 M | - | - |
Total Shareholders Equity |
349 M | 361 M | 554 M | 394 M | 262 M | 236 M | 208 M | 135 M | -83.1 M | -15.3 M | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet Editas Medicine
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
22.1 M | 20.5 M | 21.8 M | 24.4 M | 24.9 M | 26.9 M | 28.8 M | 32.9 M | 9.33 M | - | 13 M | 16.1 M | 18.4 M | 21.3 M | 21.6 M | 19.3 M | 19.3 M | 19.3 M | 19.3 M | 23.3 M | 23.3 M | 23.3 M | 23.3 M | 32.4 M | 32.4 M | 32.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
152 M | 153 M | 146 M | 150 M | 144 M | 142 M | 147 M | 154 M | 116 M | - | 110 M | 124 M | 130 M | 143 M | 142 M | 179 M | 179 M | 179 M | 179 M | 246 M | 246 M | 246 M | 246 M | 184 M | 184 M | 184 M | 184 M | 165 M | 165 M | 165 M | 165 M | 94.6 M | 94.6 M | 94.6 M | 94.6 M | 32.6 M | 32.6 M | 32.6 M | 32.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
14.7 M | 14.7 M | 14.7 M | 8.22 M | 8.22 M | 8.22 M | 8.22 M | 8.22 M | 4.22 M | - | 5.82 M | 11.3 M | 22.7 M | 34 M | 32.7 M | 20.9 M | 20.9 M | 20.9 M | 20.9 M | 23.5 M | 23.5 M | 23.5 M | 23.5 M | 15.7 M | 15.7 M | 15.7 M | 15.7 M | 13.2 M | 13.2 M | 13.2 M | 13.2 M | 256 K | 256 K | 256 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-1.42 B | -1.36 B | -1.29 B | -1.23 B | -1.21 B | -1.17 B | -1.13 B | -1.08 B | -1.02 B | - | -908 M | -858 M | -816 M | -777 M | -722 M | -665 M | -665 M | -665 M | -665 M | -549 M | -549 M | -549 M | -549 M | -416 M | -416 M | -416 M | -416 M | -306 M | -306 M | -306 M | -306 M | -186 M | -186 M | -186 M | -186 M | -88.3 M | -88.3 M | -88.3 M | -88.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
328 M | 385 M | 440 M | 499 M | 505 M | 542 M | 464 M | 514 M | 531 M | - | 623 M | 677 M | 717 M | 756 M | 780 M | 573 M | 573 M | 573 M | 573 M | 509 M | 509 M | 509 M | 509 M | 420 M | 420 M | 420 M | 420 M | 373 M | 373 M | 373 M | 373 M | 229 M | 229 M | 229 M | 229 M | 149 M | 149 M | 149 M | 149 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
95.8 M | 64.4 M | 69.2 M | 124 M | 82.5 M | 221 M | 129 M | 142 M | 215 M | 173 M | 215 M | 204 M | 264 M | 338 M | 355 M | 140 M | 140 M | 140 M | 140 M | 238 M | 238 M | 238 M | 238 M | 135 M | 135 M | 135 M | 135 M | 147 M | 147 M | 147 M | 147 M | 185 M | 185 M | 185 M | 185 M | 143 M | 143 M | 143 M | 143 M | 10.6 M | - | - | - | 2.01 M | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
176 M | 232 M | 294 M | 349 M | 360 M | 400 M | 317 M | 361 M | 415 M | - | 513 M | 554 M | 587 M | 613 M | 638 M | 394 M | 394 M | 394 M | 394 M | 262 M | 262 M | 262 M | 262 M | 236 M | 236 M | 236 M | 236 M | 208 M | 208 M | 208 M | 208 M | 135 M | 135 M | 135 M | 135 M | 117 M | 117 M | 117 M | 117 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
176 M | 232 M | 294 M | 349 M | 360 M | 400 M | 317 M | 361 M | 415 M | 465 M | 513 M | 554 M | 587 M | 613 M | 638 M | 394 M | 394 M | 394 M | 394 M | 262 M | 262 M | 262 M | 262 M | 236 M | 236 M | 236 M | 236 M | 208 M | 208 M | 208 M | 208 M | 135 M | 135 M | 135 M | 135 M | -83.1 M | -83.1 M | -83.1 M | -83.1 M | -15.3 M | - | - | - | -1.76 M | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency